InsidersTradesSigma
Track the Iqvia Holdings INC. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Iqvia Holdings INC. has logged 134 insider filings. Market capitalisation: €43bn. The latest transaction was filed on 4 September 2026 (Levée d'options). Among the most active insiders: BOUSBIB ARI. All data is openly available.
134
Insider Decl.
n/a
Thresholds
€247,135
3 ops.
Buy Volume
€176m
23 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Iqvia Holdings INC. Strong Buy (bullish), based on 18 analysts. Average price target: US$275.17.
32Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 14,325 of 29,062 companies
52.4
score / 100
Value49
Quality56
FCF yld4.8%
Earn yld3.2%
EV/EBITDA17.0x
ROE23%
Gross mgn33%
Net mgn8.3%
Debt/EBITDA4.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations134 total
5,381 shares@ US$131.820.0017% mcap33.5% of flowCommon StockSEC:0001628280-26-060755:0
2,668 shares@ US$261.330.0016% mcap32.9% of flowCommon StockSEC:0001628280-26-060755:1
2,713 shares@ US$261.540.0017% mcap33.5% of flowCommon StockSEC:0001628280-26-060755:2
1,855 shares@ US$235.270.0011% mcap87.5% of flowCommon StockSEC:0001628280-26-052701:0
5,500 shares@ US$232.680.0033% mcap34.1% of flowCommon StockSEC:0001628280-26-052703:0
5,500 shares@ US$232.680.0033% mcap100.0% of flowCommonSEC144:0001950047-26-007499
1,855 shares@ US$235.26990.0011% mcap100.0% of flowCommonSEC144:0001950047-26-007452
5,000 shares@ US$249.160.0032% mcap26.7% of flowCommon StockSEC:0001628280-26-051451:0
4,584 shares@ US$246.850.0029% mcap1.7% of flowCommon StockSEC:0001628280-26-051449:2
44,039 shares@ US$246.080.027% mcap16.5% of flowCommon StockSEC:0001628280-26-051449:3
156,206 shares@ US$78.210.031% mcap18.6% of flowCommon StockSEC:0001628280-26-051449:0
4,465 shares@ US$247.100.0028% mcap1.7% of flowCommon StockSEC:0001628280-26-051449:1
53,191 shares@ US$244.780.033% mcap19.8% of flowCommon StockSEC:0001628280-26-051449:4
47,858 shares@ US$244.600.030% mcap17.8% of flowCommon StockSEC:0001628280-26-051449:5
2,069 shares@ US$247.000.0013% mcap0.8% of flowCommon StockSEC:0001628280-26-051449:6
558 shares@ US$245.210.0003% mcap46.4% of flowCommon StockSEC:0001628280-26-051450:0
106,279 shares@ US$245.50380.066% mcap100.0% of flowCommonSEC144:0001950047-26-007379
558 shares@ US$245.210.0003% mcap100.0% of flowCommonSEC144:0001950047-26-007386
5,000 shares@ US$249.1550.0031% mcap100.0% of flowCommonSEC144:0001950047-26-007383
1,571 shares0Common StockSEC:0001628280-26-027596:0
1,571 shares0Common StockSEC:0001628280-26-027604:0
1,571 shares0Common StockSEC:0001628280-26-027607:0
1,571 shares0Common StockSEC:0001628280-26-027609:0
123 shares@ US$166.9415.6% of flowCommon StockSEC:0001628280-26-008659:0
20 shares@ US$166.94100.0% of flowCommon StockSEC:0001628280-26-008661:0
25 of 134 declarations
关于 Iqvia Holdings INC.
IQVIA Holdings Inc. (纽约证券交易所代码：IQV) 是生命科学和医疗保健服务领域的全球领先企业，业务涵盖数据、技术和临床研究。公司总部位于美国北卡罗来纳州达勒姆，业务遍及100多个国家，拥有约93,000名员工。IQVIA于2016年由Quintiles和IMS Health合并而成，合并后的公司于2017年采用IQVIA品牌。（[iqvia.com](https://www.iqvia.com/about-us)) IQVIA的商业模式现在围绕两个核心运营支柱构建。在研发方面，公司提供临床试验服务、患者和站点解决方案、中央实验室服务、功能外包和研发咨询。在商业方面，IQVIA为制药和其他医疗保健客户提供分析、市场情报、商业参与服务、患者支持和决策支持工具。其IQVIA Connected Intelligence平台和医疗级AI能力是其价值主张的核心，连接了医疗保健数据、技术和领域专业知识。（[iqvia.com](https://www.iqvia.com/about-us)) 从竞争角度来看，IQVIA之所以脱颖而出，是因为它将行业最深厚的数据资产与全球临床执行能力以及日益复杂的软件和分析产品相结合。这使其成为大型制药公司、生物技术公司、医疗技术公司、支付方和某些公共部门组织的战略合作伙伴。公司还受益于广泛的治疗领域覆盖，涵盖肿瘤学、罕见病、心血管护理、疫苗、中枢神经系统疾病和内分泌学。（[iqvia.com](https://www.iqvia.com/about-us)) IQVIA的国际影响力是其在行业中的关键优势，因为跨国试验、复杂的法规和真实世界证据的生成都需要跨国规模。公司的服务应用于临床开发、商业化、安全和医疗保健情报工作流程，使其在生物制药价值链中实现多元化布局。（[iqvia.com](https://www.iqvia.com/about-us)) 最近的发展强化了这一战略定位。2026年5月，IQVIA公布了强劲的2026年第一季度业绩，两大业务板块均实现增长，并重申了2026年全年业绩指引。2026年早些时候，公司还简化了内部运营模式，宣布了一项战略性商业数据合作，并签署了一项协议，收购Charles River Laboratories的药物发现资产，以扩展其端到端发现能力。总而言之，这些举措表明公司越来越专注于人工智能、运营效率，并将其业务范围进一步扩展到制药价值链的上游和下游。（[ir.iqvia.com](https://ir.iqvia.com/press-releases/press-release-details/2026/IQVIA-Reports-First-Quarter-2026-Results/default.aspx?utm_source=openai))
